David Shapiro Insider Sell
David Shapiro, the well informed man, presently the CMO and EVP – Development of Intercept Pharmaceuticals Inc unloaded almost 3,545 shares of the firm with a market value $585,200 US Dollars totalled based on 165.1 US Dollars of a share. David Shapiro’s sell was executed on September 28, 2016 and was unveiled in a report at the Washington-based Security and Exchange Commission’s website. The regulatory filing shows that David Shapiro now has rights to exactly 0.19% of the New York-based company’s total market cap
Out of 15 analysts covering Intercept Pharma (NASDAQ:ICPT), 8 rate it a “Buy”, 4 “Sell”, while 3 “Hold”. This means 53% are positive. $423 is the highest target while $58 is the lowest. The $184.33 average target is 9.93% above today’s ($167.68) stock price. Intercept Pharma has been the topic of 21 analyst reports since October 28, 2015 according to StockzIntelligence Inc. Laidlaw downgraded the stock on August 5 to “Sell” rating. JMP Securities maintained it with “Market Outperform” rating and $200 target price in a May 31 report. Cantor Fitzgerald initiated the shares of ICPT in a report on July 6 with “Sell” rating. Cowen & Co maintained the firm’s rating on May 31. Cowen & Co has “Outperform” rating and $215 price target. Lastly, Morgan Stanley maintained the stock with “Underweight” rating in a May 31 report.
Insitutional Activity: The institutional sentiment increased to 1.15 in 2016 Q2. Its up 0.32, from 0.83 in 2016Q1. The ratio improved, as 32 funds sold all Intercept Pharmaceuticals Inc shares owned while 43 reduced positions. 28 funds bought stakes while 58 increased positions. They now own 20.08 million shares or 7.50% more from 18.68 million shares in 2016Q1.
Carmignac Gestion holds 2.43% of its portfolio in Intercept Pharmaceuticals Inc for 1.99 million shares. Element Capital Management Llc owns 95,512 shares or 2.06% of their US portfolio. Moreover, Rtw Investments Llc has 1.93% invested in the company for 39,500 shares. The New York-based Orbimed Advisors Llc has invested 1.67% in the stock. Bb Biotech Ag, a Switzerland-based fund reported 255,719 shares.
The stock decreased 2.59% or $4.45 during the last trading session, hitting $167.68. Intercept Pharmaceuticals Inc (NASDAQ:ICPT) has risen 49.35% since February 25, 2016 and is uptrending. It has outperformed by 38.10% the S&P500.
Intercept Pharmaceuticals, Inc. is a biopharmaceutical company. The company has a market cap of $4.30 billion. The Firm is focused on the development and commercialization of therapeutics to treat non-viral, progressive liver diseases. It currently has negative earnings. The Company’s product candidates have the potential to treat orphan and more prevalent diseases for which there are limited therapeutic solutions.
According to Zacks Investment Research, “Intercept Pharmaceuticals Inc. is a biopharmaceutical company focused on the development and commercialization of therapeutics to treat chronic liver disease. The company’s lead product candidate, obeticholic acid, or OCA, is a bile acid analog and first-in-class agonist of the farnesoid X receptor (FXR). OCA is initially being developed for the second line treatment of primary biliary cirrhosis (PBC). Intercept Pharmaceuticals Inc. is headquartered in New York.”
Analysts await Intercept Pharmaceuticals Inc (NASDAQ:ICPT) to report earnings on November, 14. They expect $-3.72 earnings per share, down 77.14% or $1.62 from last year’s $-2.1 per share. After $-3.14 actual earnings per share reported by Intercept Pharmaceuticals Inc for the previous quarter, Wall Street now forecasts 18.47% negative EPS growth.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.